Keywords: gilead, 3rd-qtr, losses, hit, 52m, corus, buy
Gilead's 3rd-qtr losses hit $52M on Corus buy
Article | 30 October 2006
California, USA-based drugmaker Gilead Sciences says that it losses for the third quarter of 2006 were $52.2 million, or $0.11 per share, compared ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
